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1 |  INTRODUCTION
SRD5A2 mutations have been reported to cause an autosomal 
recessive form of male pseudohermaphroditism (disorders of 
sex development: SDS). Here, a novel mutation in SRD5A2 
gene is reported in an Iranian patient with pseudohermaphro-
ditism. A 5-month-old infant with female genitalia referred 
to endocrinology clinic at Pediatric Center of Excellence. 
Existence of testes was confirmed by ultrasonography. 
Karyotype showed a 46,XY DSD. Molecular analysis in-
cluding PCR and sequencing of SRD5A2 showed a novel 
variant in this gene. In silico analyses were also performed 
to determine the potential pathogenecity of this muta-
tion. Sequencing of SRD5A2 gene showed a novel variant, 
c.476T  >  G (p.Ile159Arg). The variant was heterozygous 
in the patient's parents. Prediction analysis using available 
software tools such as PROVEAN and Phyre2 was consis-
tent with pathogenicity of the variant. Considering that the 
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Abstract
Deficiency of the 5-alpha-reductase may have an important role in 46,XY DSD in 
some cohorts. The prenatal ultrasonography and karyotyping can trigger the attention 
toward the presence of a DSD in fetus.
K E Y W O R D S
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5-alpha-reductase deficiency unlike other diseases can be 
treated at pubertal age, early diagnosis could be helpful in 
treatment strategies in addition to prevention programs. In 
silico analysis is helpful to predict the pathogenicity of novel 
variants.
Disorders of sex development (DSDs) are congenital 
anomalies, in which there is atypical development of sex-
ual tissues.1,2 DSDs are categorized into several etiological 
groups; congenital adrenal hyperplasia (CAH), complete 
androgen insensitivity syndrome (CAIS), partial androgen 
insensitivity syndrome (PAIS), and 5-alpha-reductase defi-
ciency (5ARD) are the most common causes of DSDs.3
SRD5A2 mutations have been reported to cause an auto-
somal recessive form of DSD. This gene, located on 2p23.1, 
encodes the 5-alpha-reductase which converts testosterone to 
dihydrotestosterone (DHT). DHT is required for development 
of normal male external genitalia.4 Patients with the SRD5A2 
mutations may have variable clinical features from complete 
female genitalia, genital ambiguity to undervirilized male 
genitalia.5,6 Signs such as bifid scrotum, clitoral-like phallus, 
cryptorchidism, and pseudovaginal perineoscrotal hypospa-
dias may be observed in patients.3,7
More than one hundred SRD5A2 mutations have been 
reported at Human Gene Mutation Database (http://www.
hgmd.cf.ac.uk/ac/index.php). Some mutations are frequent in 
specific populations, and ethnic-specific prevalence of mu-
tations has been described.5 In this study, a novel variant in 
SRD5A2 gene is described in an Iranian patient. The pathoge-
nicity of this variant is also confirmed.
2 |  METHODS
2.1 | Case presentation and workup
A 5-month-old infant with female genitalia was referred to 
the endocrinology clinic (Figure  1A). Prenatal screening 
(amniocentesis) had showed a 46,XY karyotype. However, 
repeated ultrasonogrphic findings reported female genitalia. 
The initial karyotype 46,XY and the prenatal ultrasonogra-
phy which showed female external genitalia triggered the at-
tention toward the probable presence of a DSD in this child. 
At 5th month after birth, an ultrasound was performed and 
reported no testicles, but second ultrasound confirmed the 
existence of both testicles in the inguinal canals.
There were no report of ovaries or uterus in the ultra-
sounds, and there was a pseudovagina. Regarding the lack of 
electrolyte imbalance and definite female genitalia during first 
5 months, it was unlikely that the patient had congenital ad-
renal hyperplasia. Therefore, 46,XY DSD was noted for this 
F I G U R E  1  Pedigree of the family 
(A) and electropherograms (B) of normal, 
the patient and his parents; c.476T > G 
substitution causes Ile to Arg at position 159 
of protein. The parents are heterozygotes for 
this variant, and the patient is homozygote




LH 1.02 1-9 2-10 IU/L
FSH 0.25 1-10 20-50 IU/L
17OHP 66.2 20-100 20-100 ng/dL
Testosterone/DHT 25 275-875 23-75 ng/dL
Free testosterone 0.0 0.4-0.9 0.15-0.6 pg/mL
Na (Sodium) 130 135-145 135-145 mEq/L
K (Potassium) 3.5 3.7-5.9 3.7-5.9 mEq/L
Abbreviations: 17OHP, 17-hydroxyprogesterone; DHT, dihydrotestosterone; 
FSH, follicle-stimulating hormone; LH, Luteinizing hormone.
T A B L E  2  Primer sequences for coding regions of SRD5A2 in this 
study
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patient. Human chorionic gonadotropin test with three dos-
ages was performed to assess the function of testosterone and 
its receptor and to furthermore rule out the androgen insen-
sitivity syndrome and deficiency in 5-alpha-reductase. The 
results of biochemical tests for the patient showed normal go-
nadotropins, normal electrolytes, slightly increased testoster-
one, and increased testosterone/dihydrotestosterone ratio (25) 
(summarized in Table 1). Then, 5-alpha-reductase deficiency 
was suspected, for which molecular genetic testing was per-
formed; a pathogenic homozygous mutation in SRD5A2 gene 
was detected in the patient. Both parents were heterozygote for 
this mutation (Figure 1B).
2.2 | Genetic testing
An informed consent form was signed by the patient's par-
ents; 5 mL of peripheral whole blood was taken from the pa-
tient. Genomic DNA was extracted using standard salting out 
protocol. Quantity of DNA was assessed using a spectropho-
tometer (NanoDrop ND2000c; Thermo Scientific).
The coding regions and exon-intron boundaries of SRD5A2 
(NG_008365.1; NM_000348.3) were amplified using the 
forward and reverse primers (Table 2). Briefly, PCR was per-
formed in a final volume of 50 µL reagents; forward and re-
verse primers (10 pmol), template DNA (150 ng), Taq DNA 
polymerase (0.2 units/µL), MgCl2 (1.5 mmol/L), and dNTPs 
(0.4 mmol/L for each nucleotide) were used to amplify the 
regions by the following PCR program: initial denaturation 
5  minutes at 94°C and 30 cycles for denaturation at 94°C 
(30  seconds), annealing at 62°C (30  seconds), extension at 
72°C (30 seconds), and final extension at 72°C (7 minutes). 
The PCR products were directly sequenced using a sequenc-
ing analyzer ABI PRISM™ 3500 (PE Applied Biosystems) 
by a BigDye termination method.
Available online software tools including sorting intolerant 
from tolerant (SIFT), PROVEAN, combined annotation-de-
pendent depletion (CADD), and polymorphism phenotyping 
(PolyPhen-2 v2.1) were applied to predict pathogenic scores 
of the variant.
A multiple amino acid sequence alignment was done 
using UniProt protein family members (UniProtKB/
F I G U R E  2  A, Amino acid alignment of SRD5A2 protein among different orthologous and paralogous members adapted from UniProt protein 
family members. p.Ile159 (indicated in the box) is a highly conserved residue in this protein among different species. B, Phyre 2 prediction for 
effect of p.Ile159Arg on secondary structure of SRD5A2 protein
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Swiss-Prot P31213) to check conservation of the mutated 
residue (Figure  2). Protein homology/analogy recognition 
engine V2.0 (Phyre2) and iterative threading assembly re-
finement (I-TASSER) server were used to predict the effects 
of variant on the function and structure of protein.
3 |  RESULTS
One benign homozygous variant, c.265C > G (p.Leu89Val), 
was found in the patient as well as a novel variant of unknown 
significance (VUS), c.476T > G (p.Ile159Arg). Testing both 
parents for this mutation also showed that parents are hete-
rozygote for this mutation. According to ClinVar, c.265C > G 
is a benign variant with a high frequency in normal popula-
tion; thus, we did not check the benign variant in the parents. 
In silico analyses predicted the pathogenicity of this variant 
using PROVEAN (score of −6.715). Alignment analysis 
showed that p.Ile159 is a conserved amino acid (Figure 2). 
Phyre2 predicted p.Ile159Arg affects the secondary structure 
of the protein.
4 |  DISCUSSION
The SRD5A2 gene encoding steroid 5-alpha-reductase 2 is 
responsible for converting testosterone to dihydrotestoster-
one (DHT) using a double-bounded reduction. Recent studies 
have shown this enzyme is localized in endoplasmic reticulum 
(ER).8 Schematics of the SRD5A2 protein is shown in Figure 3. 
Normal plasma level of DHT is required for masculinization 
in male. Regarding female genitalia with male karyotype and 
clear increased testosterone/dihydrotestosterone ratio (25) after 
the HCG test, we aimed to check 5-alpha-reductase deficiency 
and genetic testing was performed for this patient.
A novel variant, c.476T > G (p.Ile159Arg), was found in 
our patient. Testing family members for this mutation showed 
only the patient is homozygote for the variant, and both par-
ents are heterozygotes. This variant has not been reported in 
databases such as ExAc, 1000genomes, and Iranome as well as 
HGMD and disease-specific databases. Online software tools 
also predicted that it may act as a pathogenic variant. On the 
other hand, alignment analysis using UniProt showed p.Ile159 
is conserved among other species (Figure 2); that is, it may have 
F I G U R E  3  Schematic possible structure of microsomal 5-alpha-reductase domains based on (A) UniProt database annotation and (B) Phyre 2 
prediction. p.Ile159Arg is located in a transmembrane domain
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an important role in this protein. p.Ile159 is located in a trans-
membrane domain; when it is substituted by arginine, the sec-
ondary structure of this domain may be affected. Our previous 
studies have shown that Iranian subpopulations have specific 
mutations with different frequencies in various disorders.9–11
Avendaño et al5 reviewed 256 patients with 46XY DSD; cli-
toromegaly and hypospadias were found in 66% and 40% of pa-
tients, respectively, while our patient did not show microphalus 
or hypospadias. Furthermore, in the current study, there were 
no significant abnormal urogenital characteristics. In addition, 
cryptorchidism was reported in about 20% of these patients but 
in the current study, the existence of testes in inguinal region 
bilaterally was confirmed. Interestingly, as found in our patient, 
all cases in Avendaño's study showed virilization at puberty.
As we know patients with 5-alpha-reductase deficiency un-
like other diseases can be repaired at pubertal age, thus, it is 
recommended to pay special attention to this disease and to de-
termine gene mutation of patients at early stages. In silico anal-
ysis is helpful to predict the pathogenicity of novel variants.
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